Literature DB >> 21893543

Evaluation of vaccines against enteric infections: a clinical and public health research agenda for developing countries.

John Clemens1.   

Abstract

Enteric infections are a major cause of morbidity and mortality in developing countries. To date, vaccines have played a limited role in public health efforts to control enteric infections. Licensed vaccines exist for cholera and typhoid, but these vaccines are used primarily for travellers; and there are two internationally licensed vaccines for rotavirus, but they are mainly used in affluent countries. The reasons that enteric vaccines are little used in developing countries are multiple, and certainly include financial and political constraints. Also important is the need for more cogent evidence on the performance of enteric vaccines in developing country populations. A partial inventory of research questions would include: (i) does the vaccine perform well in the most relevant settings? (ii) does the vaccine perform well in all epidemiologically relevant age groups? (iii) is there adequate evidence of vaccine safety once the vaccines have been deployed in developing countries? (iv) how effective is the vaccine when given in conjunction with non-vaccine cointerventions? (v) what is the level of vaccine protection against all relevant outcomes? and (vi) what is the expected population level of vaccine protection, including both direct and herd vaccine protective effects? Provision of evidence addressing these questions will help expand the use of enteric vaccines in developing countries.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21893543      PMCID: PMC3146771          DOI: 10.1098/rstb.2011.0033

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  38 in total

1.  Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis.

Authors:  Guillermo M Ruiz-Palacios; Irene Pérez-Schael; F Raúl Velázquez; Hector Abate; Thomas Breuer; SueAnn Costa Clemens; Brigitte Cheuvart; Felix Espinoza; Paul Gillard; Bruce L Innis; Yolanda Cervantes; Alexandre C Linhares; Pío López; Mercedes Macías-Parra; Eduardo Ortega-Barría; Vesta Richardson; Doris Maribel Rivera-Medina; Luis Rivera; Belén Salinas; Noris Pavía-Ruz; Jorge Salmerón; Ricardo Rüttimann; Juan Carlos Tinoco; Pilar Rubio; Ernesto Nuñez; M Lourdes Guerrero; Juan Pablo Yarzábal; Silvia Damaso; Nadia Tornieporth; Xavier Sáez-Llorens; Rodrigo F Vergara; Timo Vesikari; Alain Bouckenooghe; Ralf Clemens; Béatrice De Vos; Miguel O'Ryan
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

2.  Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.

Authors:  Timo Vesikari; David O Matson; Penelope Dennehy; Pierre Van Damme; Mathuram Santosham; Zoe Rodriguez; Michael J Dallas; Joseph F Heyse; Michelle G Goveia; Steven B Black; Henry R Shinefield; Celia D C Christie; Samuli Ylitalo; Robbin F Itzler; Michele L Coia; Matthew T Onorato; Ben A Adeyi; Gary S Marshall; Leif Gothefors; Dirk Campens; Aino Karvonen; James P Watt; Katherine L O'Brien; Mark J DiNubile; H Fred Clark; John W Boslego; Paul A Offit; Penny M Heaton
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

Review 3.  Direct and indirect effects in vaccine efficacy and effectiveness.

Authors:  M E Halloran; M Haber; I M Longini; C J Struchiner
Journal:  Am J Epidemiol       Date:  1991-02-15       Impact factor: 4.897

4.  Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial.

Authors:  M M Levine; C Ferreccio; S Cryz; E Ortiz
Journal:  Lancet       Date:  1990-10-13       Impact factor: 79.321

5.  Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.

Authors:  M M Levine; J B Kaper; D Herrington; J Ketley; G Losonsky; C O Tacket; B Tall; S Cryz
Journal:  Lancet       Date:  1988-08-27       Impact factor: 79.321

6.  Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis.

Authors:  Mohammad Ali; Michael Emch; Lorenz von Seidlein; Mohammad Yunus; David A Sack; Malla Rao; Jan Holmgren; John D Clemens
Journal:  Lancet       Date:  2005 Jul 2-8       Impact factor: 79.321

7.  Evaluating new vaccines for developing countries. Efficacy or effectiveness?

Authors:  J Clemens; R Brenner; M Rao; N Tafari; C Lowe
Journal:  JAMA       Date:  1996-02-07       Impact factor: 56.272

Review 8.  A review of vaccine research and development: human enteric infections.

Authors:  Marc P Girard; Duncan Steele; Claire-Lise Chaignat; Marie Paule Kieny
Journal:  Vaccine       Date:  2005-10-21       Impact factor: 3.641

9.  A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.

Authors:  R T Perry; C V Plowe; B Koumaré; F Bougoudogo; K L Kotloff; G A Losonsky; S S Wasserman; M M Levine
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

10.  Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up.

Authors:  J D Clemens; D A Sack; J R Harris; F Van Loon; J Chakraborty; F Ahmed; M R Rao; M R Khan; M Yunus; N Huda
Journal:  Lancet       Date:  1990-02-03       Impact factor: 79.321

View more
  5 in total

Review 1.  Economics and financing of vaccines for diarrheal diseases.

Authors:  Sarah M Bartsch; Bruce Y Lee
Journal:  Hum Vaccin Immunother       Date:  2014-04-22       Impact factor: 3.452

2.  Vaccines and global health.

Authors:  Brian Greenwood; David Salisbury; Adrian V S Hill
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-10-12       Impact factor: 6.237

Review 3.  Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus.

Authors:  Jai K Das; Anjali Tripathi; Anum Ali; Amman Hassan; Chesarahima Dojosoeandy; Zulfiqar A Bhutta
Journal:  BMC Public Health       Date:  2013-09-17       Impact factor: 3.295

4.  A universal polysaccharide conjugated vaccine against O111 E. coli.

Authors:  Gabrielle R Andrade; Roger R C New; Osvaldo A Sant'Anna; Neil A Williams; Rosely C B Alves; Daniel C Pimenta; Hugo Vigerelli; Bruna S Melo; Letícia B Rocha; Roxane M F Piazza; Lucia Mendonça-Previato; Marta O Domingos
Journal:  Hum Vaccin Immunother       Date:  2014-11-21       Impact factor: 3.452

5.  Total coliforms as an indicator of human enterovirus presence in surface water across Tianjin city, China.

Authors:  Jing Miao; Xuan Guo; Weili Liu; Dong Yang; Zhiqiang Shen; Zhigang Qiu; Xiang Chen; Kunming Zhang; Hui Hu; Jing Yin; Zhongwei Yang; Junwen Li; Min Jin
Journal:  BMC Infect Dis       Date:  2018-11-01       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.